

Refine Search

Search Results -

Term	Documents
(8 AND 9).PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD.	5
(L8 AND L9).PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD.	5

Database:

US Pre-Grant Publication Full-Text Database
 US Patents Full-Text Database
 US OCR Full-Text Database
 EPO Abstracts Database
 JPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

Search:

L10

Refine Search

Recall Text

Clear

Interrupt

Search History

DATE: Wednesday, June 22, 2005 [Printable Copy](#) [Create Case](#)

<u>Set Name</u> side by side	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u> result set
<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=ADJ</i>			
<u>L10</u>	18 and 19	5	<u>L10</u>
<u>L9</u>	phorbol ester	4200	<u>L9</u>
<u>L8</u>	pde4 isoenzyme	87	<u>L8</u>
<u>L7</u>	gaultherin	6	<u>L7</u>
<u>L6</u>	15 same 12	11	<u>L6</u>
<u>L5</u>	gaultheria procumbens	75	<u>L5</u>
<u>L4</u>	L3 not oil	41	<u>L4</u>
<u>L3</u>	11 same 12	906	<u>L3</u>
<u>L2</u>	water or h2o or ethanol or methanol	4040894	<u>L2</u>
<u>L1</u>	wintergreen	6430	<u>L1</u>

END OF SEARCH HISTORY

Refine Search

Search Results -

Term	Documents
(12 AND 9).PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD.	6
(L9 AND L12).PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD.	6

Database:

US Pre-Grant Publication Full-Text Database
 US Patents Full-Text Database
 US OCR Full-Text Database
 EPO Abstracts Database
 JPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

Search:

L13

Refine Search

Recall Text



Clear

Interrupt

Search History

DATE: Wednesday, June 22, 2005 [Printable Copy](#) [Create Case](#)

Set Name **Query**
 side by side

Hit Count

Set Name
 result set

DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=ADJ

L13 19 and 112 6 L13

L12 pde IV 1169 L12

DB=USPT; PLUR=YES; OP=ADJ

L11 5922557.pn. 1 L11

DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=ADJ

L10 18 and 19 5 L10

L9 phorbol ester 4200 L9

L8 pde4 isoenzyme 87 L8

L7 gaultherin 6 L7

L6 15 same 12 11 L6

L5 gaultheria procumbens 75 L5

L4 L3 not oil 41 L4

L3 11 same 12 906 L3

L2 water or h20 or ethanol or methanol
L1 wintergreen

4040894 L2
6430 L1

END OF SEARCH HISTORY

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTAU188MXM

PASSWORD:

* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *
SESSION RESUMED IN FILE 'CA, BIOSIS, MEDLINE' AT 19:35:16 ON 22 JUN 2005
FILE 'CA' ENTERED AT 19:35:16 ON 22 JUN 2005
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)
FILE 'BIOSIS' ENTERED AT 19:35:16 ON 22 JUN 2005
Copyright (c) 2005 The Thomson Corporation
FILE 'MEDLINE' ENTERED AT 19:35:16 ON 22 JUN 2005

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	117.78	117.99

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-19.72	-19.72

=> s phorbol ester?
L8 50090 PHORBOL ESTER?

=> s pde4 isoenzyme
L9 50 PDE4 ISOENZYME

=> s l9 and l8
L10 1 L9 AND L8

=> d

L10 ANSWER 1 OF 1 CA COPYRIGHT 2005 ACS on STN
AN 133:263555 CA
TI Methods for the screening of non-recombinant cell lines capable of
expressing a single **PDE4 isoenzyme** and for the
screening of PDE4 inhibitors
IN Szilagyi, Corinne
PA Warner-Lambert Co., USA
SO Eur. Pat. Appl., 21 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1041157	A2	20001004	EP 2000-400839	20000327
	EP 1041157	A3	20001011		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	US 6368815	B1	20020409	US 2000-528806	20000320
	US 2002150960	A1	20021017	US 2001-982074	20011017
	US 6635436	B2	20031021		
	US 2004058396	A1	20040325	US 2003-616275	20030708
PRAI	US 1999-126669P	P	19990329		
	US 2000-528806	A3	20000320		
	US 2001-982074	A3	20011017		

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTAU188MXM

PASSWORD:

* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *
SESSION RESUMED IN FILE 'CA, BIOSIS, MEDLINE' AT 19:52:27 ON 22 JUN 2005
FILE 'CA' ENTERED AT 19:52:27 ON 22 JUN 2005
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)
FILE 'BIOSIS' ENTERED AT 19:52:27 ON 22 JUN 2005
Copyright (c) 2005 The Thomson Corporation
FILE 'MEDLINE' ENTERED AT 19:52:27 ON 22 JUN 2005

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	131.01	131.22

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-19.72	-19.72

=> s pde IV
L11 1044 PDE IV

=> s phorbol ester
L12 39941 PHORBOL ESTER

=> s l11 and l12
L13 3 L11 AND L12

=> d 1-3 ab,bib

L13 ANSWER 1 OF 3 CA COPYRIGHT 2005 ACS on STN
AB We investigated the effects of inhibitors of cAMP-specific phosphodiesterase type IV (**PDE IV**) on cultured rat microglial cells. Microglial cells expressed mRNA encoding **PDE IV**. Rolipram and RO-20-1724, specific inhibitors of **PDE IV**, elevated the intracellular cAMP level much higher than the other types of PDE inhibitors. CAMP in astrocytes but not in cerebrocortical neurons was similarly increased in response to treatment with **PDE IV** inhibitors examined The **PDE IV** inhibitors, a β -adrenergic agonist isoproterenol and an adenylyl cyclase stimulant forskolin suppressed the proliferation of microglial cells as revealed by PCNA-immunocytochem. staining. The **PDE IV** inhibitors suppressed release of TNF α and nitric oxide (NO) from lipopolysaccharide-activated microglial cells in pure culture, while they did not affect NO release from microglial cells in neuron-microglia coculture. The **PDE IV** inhibitors also suppressed superoxide anion production by **phorbol ester**-treated microglial cells. Isoproterenol and forskolin similarly suppressed the macrophage-like functions of activated microglial cells. However, the **PDE IV** inhibitors displayed novel effects distinct from those of isoproterenol, forskolin and 8Br-cAMP, regarding expression of mRNAs encoding **PDE IV**, metallothionein-1 and hemeoxygenase-1. The present data showed that the **PDE IV** inhibitors can be available to control microglial function and that their effects on glial cells should be taken into account when **PDE IV** inhibitors are used for treatment of brain diseases, such as multiple sclerosis.

AN 137:73105 CA
TI Suppressive effects of phosphodiesterase type IV inhibitors on rat cultured microglial cells: comparison with other types of cAMP-elevating agents

AU Zhang, Bo; Yang, Lihua; Konishi, Yoshihiro; Maeda, Nobuji; Sakanaka, Masahiro; Tanaka, Junya
CS Department of Physiology, Ehime University, School of Medicine, Ehime, Japan
SO Neuropharmacology (2002), 42(2), 262-269
CODEN: NEPHBW; ISSN: 0028-3908
PB Elsevier Science Ltd.
DT Journal
LA English
RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 2 OF 3 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN

AB We investigated the effects of inhibitors of cAMP-specific phosphodiesterase type IV (**PDE IV**) on cultured rat microglial cells. Microglial cells expressed mRNA encoding **PDE IV**. Rolipram and RO-20-1724, specific inhibitors of **PDE IV**, elevated the intracellular cAMP level much higher than the other types of PDE inhibitors. cAMP in astrocytes but not in cerebrocortical neurons was similarly increased in response to treatment with **PDE IV** inhibitors examined. The **PDE IV** inhibitors, a beta-adrenergic agonist isoproterenol and an adenylyl cyclase stimulant forskolin suppressed the proliferation of microglial cells as revealed by PCNA-immunocytochemical staining. The **PDE IV** inhibitors suppressed release of TNFalpha and nitric oxide (NO) from lipopolysaccharide-activated microglial cells in pure culture, while they did not affect NO release from microglial cells in neuron-microglia coculture. The **PDE IV** inhibitors also suppressed superoxide anion production by **phorbol ester**-treated microglial cells. Isoproterenol and forskolin similarly suppressed the macrophage-like functions of activated microglial cells. However, the **PDE IV** inhibitors displayed novel effects distinct from those of isoproterenol, forskolin and 8Br-cAMP, regarding expression of mRNAs encoding **PDE IV**, metallothionein-1 and hemeoxygenase-1. The present data showed that the **PDE IV** inhibitors can be available to control microglial function and that their effects on glial cells should be taken into account when **PDE IV** inhibitors are used for treatment of brain diseases, such as multiple sclerosis.

AN 2002:208956 BIOSIS

DN PREV200200208956

TI Suppressive effects of phosphodiesterase type IV inhibitors on rat cultured microglial cells: Comparison with other types of cAMP-elevating agents.

AU Zhang, Bo; Yang, Lihua; Konishi, Yoshihiro; Maeda, Nobuji; Sakanaka, Masahiro; Tanaka, Junya [Reprint author]

CS Department of Physiology, School of Medicine, Ehime University, Ehime, Japan
jtanaka@m.ehime-u.ac.jp

SO Neuropharmacology, (February, 2002) Vol. 42, No. 2, pp. 262-269. print.
CODEN: NEPHBW. ISSN: 0028-3908.

DT Article

LA English

ED Entered STN: 20 Mar 2002

Last Updated on STN: 20 Mar 2002

L13 ANSWER 3 OF 3 MEDLINE on STN

AB We investigated the effects of inhibitors of cAMP-specific phosphodiesterase type IV (**PDE IV**) on cultured rat microglial cells. Microglial cells expressed mRNA encoding **PDE IV**. Rolipram and RO-20-1724, specific inhibitors of **PDE IV**, elevated the intracellular cAMP level much higher than the other types of PDE inhibitors. cAMP in astrocytes but not in cerebrocortical neurons was similarly increased in response to treatment with **PDE IV** inhibitors examined. The **PDE IV** inhibitors, a beta-adrenergic agonist isoproterenol and an adenylyl cyclase stimulant forskolin suppressed the proliferation of microglial cells as revealed by PCNA-immunocytochemical staining. The

PDE IV inhibitors suppressed release of TNF alpha and nitric oxide (NO) from lipopolysaccharide-activated microglial cells in pure culture, while they did not affect NO release from microglial cells in neuron-microglia coculture. The **PDE IV** inhibitors also suppressed superoxide anion production by **phorbol ester**-treated microglial cells. Isoproterenol and forskolin similarly suppressed the macrophage-like functions of activated microglial cells. However, the **PDE IV** inhibitors displayed novel effects distinct from those of isoproterenol, forskolin and 8Br-cAMP, regarding expression of mRNAs encoding **PDE IV**, metallothionein-1 and hemeoxygenase-1. The present data showed that the **PDE IV** inhibitors can be available to control microglial function and that their effects on glial cells should be taken into account when **PDE IV** inhibitors are used for treatment of brain diseases, such as multiple sclerosis.

AN 2002078980 MEDLINE
DN PubMed ID: 11804623
TI Suppressive effects of phosphodiesterase type IV inhibitors on rat cultured microglial cells: comparison with other types of cAMP-elevating agents.
AU Zhang Bo; Yang Lihua; Konishi Yoshihiro; Maeda Nobuji; Sakanaka Masahiro; Tanaka Junya
CS Department of Physiology, School of Medicine, Ehime University, Ehime, Japan.
SO Neuropharmacology, (2002 Feb) 42 (2) 262-9.
Journal code: 0236217. ISSN: 0028-3908.
CY England: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200204
ED Entered STN: 20020128
Last Updated on STN: 20020430
Entered Medline: 20020429